Best Foundayo (Orforglipron) Providers in 2026 — Ranked & Reviewed
Foundayo (orforglipron) is the first FDA-approved oral GLP-1 receptor agonist for chronic weight management, approved on April 1, 2026 by Eli Lilly. Commercial dispensing started on April 6, 2026 and the provider list is small but growing fast. We track every US telehealth platform and pharmacy confirmed as a Foundayo channel, with pricing tiers verified directly from each provider's website. The Lilly Savings Card brings the price to $25/month for commercially insured patients, $149-$299/month for cash-pay. We update this list weekly as more providers come online.
Lowest verified price: $25/mo9 providers compared
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
9 foundayo (orforglipron) providers compared · independently scored against our six-factor methodology.
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
From /mo$25Coverage50 statesMedicationsOrforglipron - Best Budget
patients with commercial insurance who want the cheapest legal brand-name GLP-1
From /mo$25Scales with doseCoverage50 statesMedicationsOrforglipron mainstream telehealth GLP-1 access
From /mo$149CoverageCheck intakeMedicationsSemaglutideTirzepatideOrforglipron- Nationwide Coverage
self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
From /mo$149Scales with doseCoverage50 statesMedicationsOrforglipronTirzepatide compounded GLP-1s from $83/mo all-in with brand Wegovy and Zepbound upgrade paths
From /mo$149Coverage36 statesMedicationsSemaglutideTirzepatideOrforglipronbroadest GLP-1 formulary including Foundayo on day-one of launch
From /mo$149CoverageCheck intakeMedicationsOrforglipronFoundayo access with a structured behavior-change program
From /mo$149Scales with doseCoverageCheck intakeMedicationsOrforgliproncompounded and brand-name GLP-1 plus a longevity stack on one platform
From /mo$149CoverageCheck intakeMedicationsSemaglutideTirzepatideOrforglipron
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings | $25 | Orforglipron | 50 states | Visit → | |
Best Budget patients with commercial insurance who want the cheapest legal brand-name GLP-1 | $25 Scales by dose | Orforglipron | 50 states | Visit → | |
 mainstream telehealth GLP-1 access | $149 | SemaglutideTirzepatideOrforglipron | Check intake | Visit → | |
Nationwide Coverage self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies | $149 Scales by dose | OrforglipronTirzepatide | 50 states | Visit → | |
 compounded GLP-1s from $83/mo all-in with brand Wegovy and Zepbound upgrade paths | $149 | SemaglutideTirzepatideOrforglipron | 36 states | Visit → | |
 broadest GLP-1 formulary including Foundayo on day-one of launch | $149 | Orforglipron | Check intake | Visit → | |
 Foundayo access with a structured behavior-change program | $149 Scales by dose | Orforglipron | Check intake | Visit → | |
 compounded and brand-name GLP-1 plus a longevity stack on one platform | $149 | SemaglutideTirzepatideOrforglipron | Check intake | Visit → |
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
Amazon One Medical
Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy, Zepbound, and Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery across roughly 3,000 US cities plus pickup kiosks at select One Medical locations. No prior membership required; insurance and cash pay both accepted. Foundayo launched at $25/month with insurance and the Lilly Savings Card, or $149/month cash pay.
Score Breakdown
Pros
- ✓As low as $1/day ($25/month) for brand-name Foundayo with insurance and the auto-applied Lilly coupon
- ✓Same-day delivery in nearly 3,000 US cities at launch, expanding to 4,500 by end of 2026
- ✓In-office pharmacist kiosks at select One Medical clinics let you walk out with Foundayo in hand
- ✓Cash-pay $5/day ($149/month) is competitive for the same FDA-approved brand-name product
- ✓Real-time availability, transparent pricing, and automatic manufacturer coupon at checkout
- ✓Delivering GLP-1 medications since 2021 — track record on cold-chain logistics
Cons
- ✗Headline $25/month needs both insurance and the Lilly Savings Card — uninsured pay $149/month
- ✗Same-day delivery is geographically gated; outside major cities it drops to next-day or slower
- ✗Pricing is set by manufacturer savings programs and can change at any time
- ✗No compounded options — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy/Zepbound pricing isn't shown upfront — depends on insurance at the prescribing visit
- ✗Copays and deductibles still apply to the clinical visit
LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Score Breakdown
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
ShedRx
Verified partnerBest for: mainstream telehealth GLP-1 access
Telehealth provider offering compounded GLP-1 medications in injectable, lozenge, and drop formats.
Score Breakdown
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
GoodRx
Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Score Breakdown
Pros
- ✓$149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- ✓$299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- ✓Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- ✓No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded
- ✓Manufacturer-direct pricing — Lilly delivers the discount through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth offers GLP-1 prescriptions ($39–$70 per visit, $19 with Gold) — one-stop for script plus card
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- ✗Self-pay only — does not apply toward insurance benefits or deductibles
- ✗Headline price applies to the lowest Foundayo dose; higher doses may cost more
- ✗No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- ✗Pricing can change as Lilly's manufacturer coupon program evolves
PreventiveMD
Best for: compounded GLP-1s from $83/mo all-in with brand Wegovy and Zepbound upgrade paths
PreventiveMD is a physician-guided telehealth platform for GLP-1 weight loss and peptide therapy, offering compounded semaglutide from $83/mo all-in and compounded tirzepatide from $97/mo all-in, plus brand Wegovy, Zepbound, and Foundayo on a membership model. A US-licensed provider reviews each request within 24 hours; approved medication ships to your door with ongoing care through an online portal.
Score Breakdown
Pros
- ✓Compounded semaglutide from $83/mo and tirzepatide from $97/mo, billed as one all-in monthly price
- ✓Brand Wegovy, Zepbound, and Foundayo (oral GLP-1) available on the same platform
- ✓US-licensed provider reviews requests within 24 hours — no video visit required
- ✓You aren't charged until a provider approves; checkout places an authorization hold only
- ✓LegitScript-certified; works exclusively with state-licensed US 503A compounding pharmacies
- ✓HSA/FSA-eligible with receipts you can submit to your insurer
- ✓Publishes its state-availability list openly on the site
Cons
- ✗Individual compounding pharmacy partners are not publicly named
- ✗Not available in 14 states + DC, including New York, New Jersey, Virginia, and Wisconsin
- ✗Brand Wegovy, Zepbound, and Foundayo require a $49/mo membership fee on top of medication cost
- ✗'As low as' pricing — actual monthly cost can be higher depending on your plan
- ✗Orders become non-refundable once provider review or pharmacy fulfillment begins
How to choose a Foundayo (orforglipron) provider
Foundayo is the first FDA-approved oral GLP-1 pill for weight loss, and the dispensing channel is new and small. Because it's a brand-name Lilly product, the differences between providers are about access, price, and legitimacy — not the medication itself.
What to look for
- Verified Foundayo channel. Foundayo is dispensed through specific pharmacies. Confirm the provider is an actual verified channel for the FDA-approved product — not a compounded 'orforglipron' substitute, which isn't a legitimate thing.
- Lilly Savings Card eligibility. For eligible commercially insured patients, the manufacturer savings card can dramatically lower the monthly cost. Ask whether the provider applies it.
- Real clinical intake. As a genuine prescription medication, Foundayo requires a proper medical review. Favor providers with a reachable clinician over instant-approval storefronts.
Red flags to avoid
- No named pharmacy or LegitScript listing. A legitimate compounded-GLP-1 provider names its 503A/503B pharmacy partner and carries LegitScript certification. If neither is disclosed, you can't verify what you're injecting.
- Async-only, no real clinician review. A prescriber should review your intake and be reachable for dose questions. Instant approval with no way to reach a clinician is a safety gap.
- Teaser pricing that hides the real cost. A low 'first month' price that jumps at higher doses, or a membership fee stacked on top of the medication, can double the true monthly total. Confirm the ongoing, all-in price before you pay.
- Weight-loss claims for B12, MIC, or HCG shots. Only GLP-1 injections have trial evidence for weight loss. A clinic selling B12, lipotropic, or HCG shots as a weight-loss treatment is a red flag.
Every provider ranked above is scored against these criteria across our six-dimension methodology, and prices are re-verified against each provider’s live site.
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Orforglipron · Drugs and brands
- Foundayo · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- STEP-1 · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.